By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Nimbus Discovery 

25 First Street
Suite 303
Cambridge  Massachusetts  02141  U.S.A.
Phone: 617-588-2600 Fax: 617-231-0652


SEARCH JOBS



Segment
Pharmaceuticals





Company News
Nimbus Discovery To Present Data Showing That Selective ACC Inhibitors Dramatically Impact Tumor Growth In Pre-Clinical Models At American Association for Cancer Research Annual Meeting 2014 4/2/2014 9:37:38 AM
Nimbus Discovery IRAK4 Inhibitor Demonstrates Synergistic Effects In Preclinical Studies With Three Kinase Inhibitors For The Treatment Of Lymphoid Malignancies 12/9/2013 9:52:55 AM
Nimbus Discovery Advances Broad Portfolio of ACC Inhibitors for Potential Treatment of Diabetes, NASH and Liver Cancer 11/1/2013 9:55:29 AM
Nimbus Discovery and Monsanto Company (MON) Announce Collaboration 6/27/2013 9:58:56 AM
Nimbus Discovery Presents Compelling Preclinical Proof of Concept Data on Novel ACC Allosteric Inhibitor ND-630 6/24/2013 11:23:29 AM
Nimbus Discovery Announces Agreement With Shire plc to Co-Develop Therapies for Rare Diseases 5/8/2013 10:58:44 AM
Nimbus Discovery Appoints William F. Westlin, Ph.D., as Head of Preclinical Research and Early Development 2/6/2013 9:31:28 AM
Nimbus Discovery IRAK4 Inhibitors Demonstrate Synergistic Effects With BTK Inhibitor Ibrutinib 12/10/2012 10:02:01 AM
Nimbus Discovery Presents Preclinical Data on Highly Selective IRAK4 Inhibitors for the Treatment of Rheumatic Diseases 11/12/2012 10:02:00 AM
Nimbus Discovery and Proteros biostructures GmbH Enter into Privileged X-Ray Crystallography Partnership Agreement 11/8/2012 10:26:19 AM
12
//-->